SCHEMBL3316509

SCHEMBL3316509

COc1ccc2cc(C3CC(c4ccc(OC)c(OC)c4)=NN3C(=O)c3ccco3)c(Cl)nc2c1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
XBP1 P17861 1/20 0.76
KMT2A Q03164 3/20 0.65
RAB9A P51151 2/20 0.65
MEN1 O00255 1/20 0.65
KDM4E B2RXH2 3/20 0.59
PKM P14618 2/20 0.59
MAPT P10636 2/20 0.54
POLB P06746 4/20 0.51
RXFP1 Q9HBX9 1/20 0.51
BLM P54132 1/20 0.49
ALDH1A1 P00352 1/20 0.47
P2RY6 Q15077 1/20 0.46
GAA P10253 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
LMNA P02545 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3312926 0.94 XBP1 (0.76) XBP1KMT2ARAB9AMEN1KDM4E
SCHEMBL3311133 0.86 MAOB (0.58) XBP1KMT2ARAB9AMEN1KDM4E
SCHEMBL3314554 0.86 XBP1 (0.57) XBP1KMT2ARAB9AMEN1KDM4E
SCHEMBL3318263 0.82 KDM4E (0.71) XBP1RAB9AKDM4EPKMMAPT
SCHEMBL23052464 0.81 KMT2A (0.78) XBP1KMT2ARAB9AMEN1KDM4E
SCHEMBL3314306 0.81 KMT2A (0.63) XBP1KMT2AMEN1KDM4EPKM
SCHEMBL3312789 0.80 KDM4E (0.65) XBP1KDM4EPKMMAPTPOLB
SCHEMBL3314649 0.79 XBP1 (0.57) XBP1KMT2ARAB9AMEN1KDM4E
SCHEMBL3312487 0.78 KDM4E (0.64) XBP1KDM4EPKMMAPTBLM
SCHEMBL20989162 0.77 KMT2A (0.78) KMT2ARAB9AMEN1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
WO-2008045663-A2 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS KALYPSYS, INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS PDE4A, PDE4B, PDE4C XBP1 2991/4885KMT2A 2514/4885RAB9A 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.